The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
 
Reagan Barnett
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - InVitro Cell Research
 
Sree M Lanka
No Relationships to Disclose
 
Keelia M. Clemens
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Lesli Ann Kiedrowski
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Hani M. Babiker
Consulting or Advisory Role - Caris Life Sciences; Celgene; Endocyte; Idera; Myovant Sciences; Sirtex Medical
Speakers' Bureau - Guardant Health
Research Funding - Novocure; Strategia
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Haley M. Meyer
No Relationships to Disclose
 
Yujin Choi
No Relationships to Disclose
 
Rohan Garje
Research Funding - Amgen (Inst); Endocyte/Advanced Accelerator Applications (Inst); Immunomedics (Inst); Pfizer (Inst); xencor (Inst)
 
Xin Gao
Consulting or Advisory Role - Bayer; Flare Therapeutics; Guardant Health; Myovant Sciences; PATHAI; PureTech; Silverback Therapeutics
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Richard Y. Chang
No Relationships to Disclose
 
Albert Jang
No Relationships to Disclose
 
Pat Gulhati
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Pedro C. Barata
Honoraria - UroToday
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst)